- ₹50-crore acquisition of Velbiom Probiotics Pvt. Ltd.’s Rx portfolio signals aggressive push into next-gen gut science
- Strategic fit to turbocharge metabolic care and women’s health franchises amid rising lifestyle disorders
- Microbiome-led therapies emerge as the new frontier in precision healthcare and chronic disease management
NE HEALTH BUREAU
AHMEDABAD, MAR 23
In a decisive move to ride India’s fast-evolving microbiome wave, Eris Lifesciences Limited has acquired the prescription probiotics business of Velbiom Probiotics Pvt. Ltd. for ₹50 crore, sharpening its focus on metabolic wellness and women’s health.
The acquisition brings into Eris’ fold a portfolio of clinically differentiated, strain-specific probiotic brands, positioning the company at the intersection of gut health, immunity, and chronic disease management.
Velbiom, known for its India-focused microbiome research, has carved a niche with disease-targeted probiotic therapies—an emerging segment gaining traction among clinicians amid rising cases of diabetes, obesity, and urogenital disorders.
Key brands acquired include:
• Lactogut — Multi-strain gastrointestinal health formulation
• Lactogut UG — Targeted solution for recurrent UTIs and urogenital wellness in women
• Lactovit — Daily gut wellness and immune support supplement
Strategic Rationale
Industry experts see this as a timely bet. The global shift toward microbiome-based interventions—especially alongside GLP-1 therapies—is redefining treatment pathways for metabolic diseases.
Amit Bakshi, CMD, Eris Lifesciences Limited, said: “Prebiotics and probiotics represent a fast-growing, high-potential adjacency to our core diabetes and cardio-metabolic franchises. The clinical synergies between GLP-1 therapies and gut microbiome health create a compelling opportunity for us to differentiate our disease management offerings.”
Healthcare analysts note that gut microbiota modulation is increasingly being linked to improved outcomes in diabetes, obesity, and even hormonal health—making probiotics a critical add-on therapy rather than just a wellness product.
Expert Take
A senior pharma market analyst commented: “This acquisition reflects a broader industry pivot—from symptomatic treatment to ecosystem-based care. Microbiome science is no longer fringe; it is central to next-generation therapeutics, especially in metabolic and women’s health segments.”
Why It Matters
With India witnessing a surge in lifestyle diseases and antibiotic resistance concerns, demand for targeted probiotic therapies is expected to rise sharply. By integrating Velbiom’s portfolio, Eris is not only expanding its product basket but also aligning with a future-ready, science-backed healthcare model.
